Difference between revisions of "Melphalan (Alkeran)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Neutral chemotherapy" to "Category:Neutral") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
(20 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
==General information== | ==General information== | ||
− | Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf Melphalan (Alkeran) package insert]</ref><ref>[[ | + | Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/014691s029lbl.pdf Melphalan (Alkeran) package insert]</ref><ref>[[:File:Melphalan.pdf|Melphalan (Alkeran) package insert (locally hosted backup)]]</ref> |
<br>Route: IV, PO | <br>Route: IV, PO | ||
<br>Extravasation: [[irritant]] or [[neutral]], depending on reference | <br>Extravasation: [[irritant]] or [[neutral]], depending on reference | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
+ | |||
+ | ==Diseases for which it is established ''(work in progress)''== | ||
+ | *[[Peripheral T-cell lymphoma]] | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
+ | *[[Acute myeloid leukemia]] | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
− | |||
− | |||
*[[Ewing sarcoma]] | *[[Ewing sarcoma]] | ||
− | *[[Follicular lymphoma]] | + | *[[Classical Hodgkin lymphoma]] |
− | *[[HIV-associated lymphoma]] | + | *[[Neuroblastoma]] |
− | *[[ | + | *Non-Hodgkin lymphoma |
− | *[[Light-chain (AL) amyloidosis]] | + | **[[CNS lymphoma]] |
− | *[[ | + | **[[Diffuse large B-cell lymphoma]] |
− | *[[ | + | **[[Follicular lymphoma]] |
− | *[[ | + | **[[HIV-associated lymphoma]] |
+ | **[[Mantle cell lymphoma]] | ||
+ | *Plasma cell dyscrasia | ||
+ | **[[Light-chain (AL) amyloidosis]] | ||
+ | **[[Multiple myeloma]] | ||
+ | **[[Plasma cell leukemia]] | ||
+ | |||
+ | ==Diseases for which it was used== | ||
+ | *[[Breast cancer - historical|Breast cancer]] | ||
+ | *[[Ovarian cancer - historical|Ovarian cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
− | *[ | + | *[https://chemocare.com/druginfo/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/Melphalan.aspx Melphalan (Alkeran) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/melphalan-patient-drug-information Melphalan (Alkeran) patient drug information (UpToDate)]</ref> | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
− | * | + | *1964-01-17: Initial FDA approval<ref>[http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=014691&DrugName=ALKERAN&ActiveIngred=MELPHALAN&SponsorApplicant=GLAXOSMITHKLINE&ProductMktStatus=1&goto=Search.Label_ApprovalHistory Melphalan (Alkeran) FDA approval history]</ref> |
− | * Indicated for the palliative treatment of [[multiple myeloma]] | + | *Uncertain date: Indicated for the palliative treatment of [[multiple myeloma]]. ''(Based on SWG01)'' |
− | + | *Uncertain date: Indicated for the palliation of non-resectable [[Ovarian_cancer|epithelial carcinoma of the ovary]]. ''(No supporting studies are cited)'' | |
+ | ==History of changes in EMA indication== | ||
+ | *1963-09-26: EURD | ||
==Also known as== | ==Also known as== | ||
*'''Generic names:''' L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard | *'''Generic names:''' L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard | ||
− | *'''Brand names:''' Alkeran, Alkerana, Levofolan, Melfalan | + | *'''Brand names:''' Alkeran, Alkerana, Evomela, Levofolan, Melfalan, Phelinun |
==References== | ==References== | ||
Line 44: | Line 57: | ||
[[Category:Nitrogen mustards]] | [[Category:Nitrogen mustards]] | ||
+ | [[Category:Acute myeloid leukemia medications]] | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
[[Category:CNS lymphoma medications]] | [[Category:CNS lymphoma medications]] | ||
Line 50: | Line 64: | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
− | [[Category:Hodgkin lymphoma medications]] | + | [[Category:Classical Hodgkin lymphoma medications]] |
[[Category:Light-chain (AL) amyloidosis medications]] | [[Category:Light-chain (AL) amyloidosis medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
+ | [[Category:Neuroblastoma medications]] | ||
+ | [[Category:Peripheral T-cell lymphoma medications]] | ||
[[Category:Plasma cell leukemia medications]] | [[Category:Plasma cell leukemia medications]] | ||
+ | |||
+ | [[Category:Breast cancer medications (historic)]] | ||
+ | [[Category:Ovarian cancer medications (historic)]] | ||
[[Category:FDA approved in 1964]] | [[Category:FDA approved in 1964]] | ||
+ | [[Category:EMA approved in 1963]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] |
Latest revision as of 01:04, 29 June 2024
General information
Class/mechanism: Nitrogen mustard, alkylator. Melphalan is a bischloroethylamine alkylating agent that crosslinks DNA by binding at the N7 position of guanine, with activity against resting and proliferating cells.[1][2]
Route: IV, PO
Extravasation: irritant or neutral, depending on reference
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is established (work in progress)
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Ewing sarcoma
- Classical Hodgkin lymphoma
- Neuroblastoma
- Non-Hodgkin lymphoma
- Plasma cell dyscrasia
Diseases for which it was used
Patient drug information
- Melphalan (Alkeran) patient drug information (Chemocare)[3]
- Melphalan (Alkeran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1964-01-17: Initial FDA approval[5]
- Uncertain date: Indicated for the palliative treatment of multiple myeloma. (Based on SWG01)
- Uncertain date: Indicated for the palliation of non-resectable epithelial carcinoma of the ovary. (No supporting studies are cited)
History of changes in EMA indication
- 1963-09-26: EURD
Also known as
- Generic names: L-PAM, L-Sacrolysin, L-Sarcolysin, MPL, phenylalanine mustard
- Brand names: Alkeran, Alkerana, Evomela, Levofolan, Melfalan, Phelinun
References
Categories:
- Drugs
- Intravenous medications
- Oral medications
- Irritant
- Neutral
- Alkylating agents
- Nitrogen mustards
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Ewing sarcoma medications
- Follicular lymphoma medications
- HIV-associated lymphoma medications
- Classical Hodgkin lymphoma medications
- Light-chain (AL) amyloidosis medications
- Mantle cell lymphoma medications
- Multiple myeloma medications
- Neuroblastoma medications
- Peripheral T-cell lymphoma medications
- Plasma cell leukemia medications
- Breast cancer medications (historic)
- Ovarian cancer medications (historic)
- FDA approved in 1964
- EMA approved in 1963
- WHO Essential Cancer Medicine